Detalles de la búsqueda
1.
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Cancer Treat Rev
; 113: 102492, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36640618
2.
Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
Cancer Treat Rev
; 119: 102585, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37392723
3.
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Cancer Rep (Hoboken)
; 6(5): e1804, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37069784
4.
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.
Cancer Treat Rev
; 97: 102172, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33989949
5.
Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy.
Front Oncol
; 9: 1522, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-32039012
Resultados
1 -
5
de 5
1
Próxima >
>>